Developer docs
API playgroundTry for free, no card

Search company profiles

Gameto

Full company profile

uuid000059a

Namestring
Gameto
Legal namestring
Gameto, Inc.
Websiteurl
gametogen.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Gameto is a clinical-stage biotechnology company developing therapeutics for the female reproductive system using engineered human induced pluripotent stem cells (hiPSCs). The company's proprietary cell engineering platform differentiates hiPSCs via transcription factor overexpression into FOXL2+ granulosa-like ovarian support cells (OSCs) and DDX4+ oogonia-like cells, which are used to mature oocytes ex vivo in a process termed OSC-IVM. Gameto operates three named programs on this platform: Fertilo, the lead program applying OSC-IVM to IVF and egg freezing; Ameno, a cell therapy for menopause symptoms (including a steroidogenic hormone-responsive bioengineered ovarian implant) supported by a $10 million ARPA-H award; and Deovo, a drug testing and development platform for ovarian disease built on the company's ovary-in-a-dish platform underpinned by exclusively licensed Harvard meiosis IP.

Fertilo, Gameto's commercial focus, reduces the conventional two-week IVF hormone injection protocol to approximately three days of minimal stimulation, achieves roughly 80% less hormone medication, and has reported MII oocyte maturation rates of approximately 71% versus approximately 43% for conventional IVM control. The therapy is cleared for commercial use in approximately 12 countries outside the United States and is investigational in the US, where a Phase 3 trial is underway at 15 clinics following FDA IND clearance in January 2025. Eleven live births via Fertilo have been reported globally, including the first live birth from an hiPSC-derived cell therapy on December 9, 2024.

Gameto generates revenue per treatment cycle outside the US through partner fertility clinics, while in the US it offers no-cost Phase 3 clinical trial enrollment via Accel Recruitment. The company is venture-backed, having raised $127 million cumulatively across Series A, B, and C rounds led by Future Ventures, RA Capital / Two Sigma Ventures, and Overwater Ventures, respectively. Its Tier-1 investor base includes Insight Partners, Lux Capital, and notable individuals such as Bob Nelsen (Arch Ventures) and Anne Wojcicki (23andMe). Gameto is incorporated in Delaware, headquartered in Austin, TX, with offices in New York (Alexandria Center for Life Sciences), Houston, Bee Cave (Texas), and a Europe regional presence in Spain.

Short descriptiontext

Gameto is a clinical-stage biotechnology company engineering iPSC-derived ovarian support cells for women's reproductive health. Its lead program, Fertilo, is an OSC-IVM cell therapy for IVF and egg freezing currently in US Phase 3 trials and commercially cleared in approximately 12 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy therapeutics, reproductive health biotechnology, IVF treatment solutions, iPSC ovarian support cells, women's health biotechnology
Industry1 code
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cell Therapy
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pre-commercial / Investigational therapy revenues
TypeUsage Based
Description

Fertilo is an investigational biologic in the U.S. Phase 3 trial with no FDA approval and no marketed revenue in the U.S. Outside the U.S. the therapy is offered commercially through partner clinics in approximately 12 countries, generating procedure-based / unit-based revenue per treatment cycle. Infertility impacts 1 in 6 people globally, defining the addressable market.

gametogen.com
2Non-dilutive grant funding (ARPA-H)
TypeManaged Services
Description

$10 million award through ARPA-H's Sprint for Women's Health Initiative to accelerate the Ameno menopause program.

gametogen.com
3Equity capital raises (private)
TypeSubscription Recurring
Description

Recurring venture capital financings including a $44 million Series C (2025) and a $43,999,930 exempt securities offering (Form D, Aug 2025); cumulative funding of $127 million across Series A, B, and C from Insight Partners, Future Ventures, RA Capital, Two Sigma Ventures, Lux Capital, Overwater and others.

sec.gov
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1US clinical trial enrollment (no-cost) and ex-US partner-clinic commercial access
ModelOtherBilling cadencePay-as-you-go
Notes

US patients: free enrollment in Phase 3 clinical trial via accelrecruitment.com; commercial Fertilo pricing per treatment cycle outside the US is set by partner clinics and is not publicly disclosed.

gametogen.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Fertilo
Description

Gameto's lead program — an engineered ovarian support cell-based IVF therapy that matures eggs outside the body, making IVF and egg freezing shorter, easier, and more accessible.

gametogen.com
+2 more records
Core offering1 text field

Gameto is a clinical-stage biotechnology company that develops cell-engineered therapeutics for the female reproductive system using induced pluripotent stem cell (iPSC) technology. Its lead program, Fertilo, is an investigational OSC-IVM (ovarian support cell in vitro maturation) biologic that co-cultures immature oocytes with iPSC-derived ovarian support cells to mature eggs outside the body in approximately 24 hours, reducing the standard two-week IVF hormone injection protocol to about three days. The company also operates two additional programs: Ameno, a cell therapy targeting menopause symptoms, and Deovo, a drug screening platform for ovarian disease built on Gameto's licensed Harvard meiosis IP.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • ~80% reduction in hormone medication burden vs. conventional IVF
+5 more records
Product overview1 text field

Gameto offers a unified cell engineering platform that powers a portfolio of three named programs targeting women's reproductive health: Fertilo (the lead program, an investigational cell therapy for IVF and egg freezing using iPSC-derived ovarian support cells currently in U.S. Phase 3 trials), Ameno (a cell therapy program for menopause symptoms, including a bioengineered ovarian implant), and Deovo (a drug testing and development platform for ovarian disease). The shared platform—developed with Harvard Medical School and the Wyss Institute—uses transcription factor-directed differentiation of human induced pluripotent stem cells (hiPSCs) into ovarian support cells, and was recently extended with a Harvard meiosis IP license to enable the company's ovary-in-a-dish platform.

Product and service3 records
1Fertilo
CategoryLead Program (Cell Therapy)
Description

Gameto's lead investigational cell therapy that uses iPSC-derived engineered ovarian support cells (OSCs) to mature eggs outside the body via OSC-IVM. Designed to make IVF and egg freezing shorter, easier, and more accessible by replacing the conventional ~two-week hormone injection protocol with about three days of minimal stimulation, with engineered cells nurturing eggs for approximately 24 hours before fertilization or freezing. Currently advancing through a U.S. Phase 3 clinical trial at 15 clinics and commercially available in approximately 12 countries outside the U.S.

2Ameno
CategoryProgram (Cell Therapy)
Description

Gameto's cell therapy program for menopause, leveraging proprietary cell engineering to delay the unwanted effects of menopause. Includes development of a steroidogenic hormone-responsive bioengineered ovarian implant with alginate encapsulation of hiPSC-derived ovarian support cells, designed for long-term hormone restoration to address menopause symptoms in the over 1 billion women globally who will experience menopause.

3Deovo
CategoryProgram (Drug Testing Platform)
Description

Gameto's drug testing and development program for ovarian disease, built on the company's proprietary cell engineering platform. Uses the human ovary-in-a-dish platform (incorporating licensed Harvard meiosis IP) to model human ovarian development and dysfunction for drug screening across multiple ovarian conditions. Aimed at pharmaceutical partners and biotech drug developers targeting ovarian indications.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2026-02-04
Description

Gameto has exclusively licensed intellectual property from Harvard University related to the genetic induction of early meiosis in human cells. The licensed patent portfolio covers genes and methods enabling human oogonia to enter early meiotic stages in vitro and is integrated with Gameto's ovarian organoid platform. The collaboration underpins the company's scientific foundation (CSO Christian Kramme completed his PhD at Harvard Medical School under a Sponsored Research Agreement with Gameto and Professor George Church).

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Chairman Martin Varsavsky is the founder and non-executive chairman of Prelude Fertility, the largest network of fertility clinics in the United States. The Prelude network provides a potential channel and strategic alignment for Gameto's products and was identified as the founder's flagship prior company in the fertility space.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Pietro Bortoletto serves as a Scientific & Clinical Advisor to Gameto; he is Director of Reproductive Surgery and Co-Director of Oncofertility Program at Boston IVF and Clinical Instructor at Harvard Medical School. Boston IVF is a leading US fertility clinic network.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Jaime Knopman, Director of Fertility Preservation at CCRM Fertility of New York, serves as a Scientific & Clinical Advisor to Gameto.

5Ruber de Juan Bravo Hospital (Eugin Group; Dr. Daniel Ordóñez Pérez)
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Dr. Daniel Ordóñez Pérez, Head of the Assisted Reproduction Unit at Ruber de Juan Bravo Hospital (part of Eugin Group), is a Scientific & Clinical Advisor and has conducted studies of Fertilo with his patients in Madrid, Spain.

gametogen.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Michel De Vos, Senior Medical Director at the Centre for Reproductive Medicine at Universitair Ziekenhuis Brussel, Belgium, is a Scientific & Clinical Advisor to Gameto. He is a principal investigator in the FOTO consortium and a leading IVM expert.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Professor Mary Herbert, Professor of Reproductive Biology at Newcastle University and Scientific Director at Newcastle Fertility Centre, serves as a Scientific & Clinical Advisor to Gameto.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Professor Philip Jordan (Biochemistry & Molecular Biology) and Dr. Joshua C. Doloff (Biomedical Engineering) at Johns Hopkins serve as Scientific & Clinical Advisors to Gameto.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Professor Kristin Baldwin, Professor of Genetics and Development at Columbia University and member of the Columbia Stem Cell Initiative, serves as a Scientific & Clinical Advisor to Gameto.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Professor Pranam Chatterjee, upcoming Assistant Professor at Duke University Medical School and Research Fellow at Harvard Medical School, serves as a Scientific & Clinical Advisor and is developing state-of-the-art algorithms and high-throughput experimental screens to interrogate germ cell development for Gameto. He holds patents on ScCas9, Sc++, and iSpyMac.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Accel Recruitment hosts Gameto's Phase 3 US clinical trial eligibility screening and enrollment (accelrecruitment.com/ivf-study).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Co-founded by Gameto Chairman Martin Varsavsky; focuses on automated IVF and embryo engineering. Direct comparable in cell-engineering-based reproductive medicine and shares scientific and investor DNA with Gameto.

2Conceivable Life Sciences
TypeDirect peer
Description

Directly competes with Gameto in engineered egg maturation; co-recognized alongside Gameto at the 2025 World Fertility Awards in the same category. Closest head-to-head peer in iPSC/automation-driven IVF.

TypeEmerging player
Description

Automated, software-tracked cryo-storage for frozen eggs and embryos; serves the same IVF/egg-freezing patient population as Fertilo with an adjacent technology layer rather than a cell-therapy approach.

TypeBroad incumbent
Description

One of the largest incumbents in reproductive medicine (Menopur, Bravelle, Lutrepulse) and a major commercial force in IVF drugs globally. Gameto's commercial advisor Aaron Graff is ex-CEO of Ferring USA, underscoring the direct competitive overlap.

5Merck KGaA (Life Science / Healthcare)
TypeBroad incumbent
Description

Sells Gonal-f (recombinant FSH), one of the gold-standard ovarian stimulation drugs for IVF. Sets the existing standard-of-care protocol that Fertilo's minimal-stimulation approach is designed to disrupt.

TypeBroad incumbent
Description

Spun out of Merck with a focused women's health portfolio including fertility (e.g., Ganirelix, Follistim) and biosimilars. A likely strategic acquirer or competitor for any approved iPSC fertility therapy.

TypeBroad incumbent
Description

Supplies IVF media, culture tools, and time-lapse incubation systems used in conventional IVF labs worldwide. Competes for clinic wallet share and partnership attention even though its offering is consumables rather than cell therapy.

TypeBroad incumbent
Description

Public fertility benefits manager that sits between employers, clinics, and patients; relevant peer for understanding payer-side adoption dynamics and channel access that any approved Fertilo launch must navigate.

TypeBroad incumbent
Description

Operates a national network of fertility clinics and is also a major employer fertility benefits provider; competes with Gameto for clinic channel mindshare and represents a potential commercial partner or acquirer.

TypeOthers
Description

Bayer-owned iPSC-derived cell therapy company (e.g., Parkinson's program); not a reproductive peer but a directly comparable iPSC platform company whose clinical and manufacturing trajectory informs investor expectations for Gameto's platform risk and timeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gameto

Cell Therapygametogen.com

Gameto is a clinical-stage biotechnology company engineering iPSC-derived ovarian support cells for women's reproductive health. Its lead program, Fertilo, is an OSC-IVM cell therapy for IVF and egg freezing currently in US Phase 3 trials and commercially cleared in approximately 12 countries.

What Gameto does

Gameto is a clinical-stage biotechnology company developing therapeutics for the female reproductive system using engineered human induced pluripotent stem cells (hiPSCs). The company's proprietary cell engineering platform differentiates hiPSCs via transcription factor overexpression into FOXL2+ granulosa-like ovarian support cells (OSCs) and DDX4+ oogonia-like cells, which are used to mature oocytes ex vivo in a process termed OSC-IVM. Gameto operates three named programs on this platform: Fertilo, the lead program applying OSC-IVM to IVF and egg freezing; Ameno, a cell therapy for menopause symptoms (including a steroidogenic hormone-responsive bioengineered ovarian implant) supported by a $10 million ARPA-H award; and Deovo, a drug testing and development platform for ovarian disease built on the company's ovary-in-a-dish platform underpinned by exclusively licensed Harvard meiosis IP.

Fertilo, Gameto's commercial focus, reduces the conventional two-week IVF hormone injection protocol to approximately three days of minimal stimulation, achieves roughly 80% less hormone medication, and has reported MII oocyte maturation rates of approximately 71% versus approximately 43% for conventional IVM control. The therapy is cleared for commercial use in approximately 12 countries outside the United States and is investigational in the US, where a Phase 3 trial is underway at 15 clinics following FDA IND clearance in January 2025. Eleven live births via Fertilo have been reported globally, including the first live birth from an hiPSC-derived cell therapy on December 9, 2024.

Gameto generates revenue per treatment cycle outside the US through partner fertility clinics, while in the US it offers no-cost Phase 3 clinical trial enrollment via Accel Recruitment. The company is venture-backed, having raised $127 million cumulatively across Series A, B, and C rounds led by Future Ventures, RA Capital / Two Sigma Ventures, and Overwater Ventures, respectively. Its Tier-1 investor base includes Insight Partners, Lux Capital, and notable individuals such as Bob Nelsen (Arch Ventures) and Anne Wojcicki (23andMe). Gameto is incorporated in Delaware, headquartered in Austin, TX, with offices in New York (Alexandria Center for Life Sciences), Houston, Bee Cave (Texas), and a Europe regional presence in Spain.

Gameto firmographics

Firmographics
Name
Gameto
Legal name
Gameto, Inc.
Website
https://gametogen.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Gameto is a clinical-stage biotechnology company engineering iPSC-derived ovarian support cells for women's reproductive health. Its lead program, Fertilo, is an OSC-IVM cell therapy for IVF and egg freezing currently in US Phase 3 trials and commercially cleared in approximately 12 countries.
Ownership category
akta.pro rank

Gameto industry classification

Industry
Product category
Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Cell therapy therapeutics
  • Reproductive health biotechnology
  • IVF treatment solutions
  • IPSC ovarian support cells
  • Women's health biotechnology

Where Gameto is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Gameto business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pre-commercial / Investigational therapy revenues: Fertilo is an investigational biologic in the U.S. Phase 3 trial with no FDA approval and no marketed revenue in the U.S. Outside the U.S. the therapy is offered commercially through partner clinics in approximately 12 countries, generating procedure-based / unit-based revenue per treatment cycle. Infertility impacts 1 in 6 people globally, defining the addressable market.
  2. Non-dilutive grant funding (ARPA-H): $10 million award through ARPA-H's Sprint for Women's Health Initiative to accelerate the Ameno menopause program.
  3. Equity capital raises (private): Recurring venture capital financings including a $44 million Series C (2025) and a $43,999,930 exempt securities offering (Form D, Aug 2025); cumulative funding of $127 million across Series A, B, and C from Insight Partners, Future Ventures, RA Capital, Two Sigma Ventures, Lux Capital, Overwater and others.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goUS clinical trial enrollment (no-cost) and ex-US partner-clinic commercial access

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Gameto product offering

Product offering

Core offering

Gameto is a clinical-stage biotechnology company that develops cell-engineered therapeutics for the female reproductive system using induced pluripotent stem cell (iPSC) technology. Its lead program, Fertilo, is an investigational OSC-IVM (ovarian support cell in vitro maturation) biologic that co-cultures immature oocytes with iPSC-derived ovarian support cells to mature eggs outside the body in approximately 24 hours, reducing the standard two-week IVF hormone injection protocol to about three days. The company also operates two additional programs: Ameno, a cell therapy targeting menopause symptoms, and Deovo, a drug screening platform for ovarian disease built on Gameto's licensed Harvard meiosis IP.

Product overview

Gameto offers a unified cell engineering platform that powers a portfolio of three named programs targeting women's reproductive health: Fertilo (the lead program, an investigational cell therapy for IVF and egg freezing using iPSC-derived ovarian support cells currently in U.S. Phase 3 trials), Ameno (a cell therapy program for menopause symptoms, including a bioengineered ovarian implant), and Deovo (a drug testing and development platform for ovarian disease). The shared platform—developed with Harvard Medical School and the Wyss Institute—uses transcription factor-directed differentiation of human induced pluripotent stem cells (hiPSCs) into ovarian support cells, and was recently extended with a Harvard meiosis IP license to enable the company's ovary-in-a-dish platform.

Differentiator

Problem solved

Functional benefit

Brands

  • Fertilo: Gameto's lead program — an engineered ovarian support cell-based IVF therapy that matures eggs outside the body, making IVF and egg freezing shorter, easier, and more accessible.
  • Ameno
  • Deovo

Products and services

  • Fertilo Gameto's lead investigational cell therapy that uses iPSC-derived engineered ovarian support cells (OSCs) to mature eggs outside the body via OSC-IVM. Designed to make IVF and egg freezing shorter, easier, and more accessible by replacing the conventional ~two-week hormone injection protocol with about three days of minimal stimulation, with engineered cells nurturing eggs for approximately 24 hours before fertilization or freezing. Currently advancing through a U.S. Phase 3 clinical trial at 15 clinics and commercially available in approximately 12 countries outside the U.S.
  • Ameno Gameto's cell therapy program for menopause, leveraging proprietary cell engineering to delay the unwanted effects of menopause. Includes development of a steroidogenic hormone-responsive bioengineered ovarian implant with alginate encapsulation of hiPSC-derived ovarian support cells, designed for long-term hormone restoration to address menopause symptoms in the over 1 billion women globally who will experience menopause.
  • Deovo Gameto's drug testing and development program for ovarian disease, built on the company's proprietary cell engineering platform. Uses the human ovary-in-a-dish platform (incorporating licensed Harvard meiosis IP) to model human ovarian development and dysfunction for drug screening across multiple ovarian conditions. Aimed at pharmaceutical partners and biotech drug developers targeting ovarian indications.

Quantifiable outcome

  • ~80% reduction in hormone medication burden vs. conventional IVF
  • +5 more outcomes

Companies that use Gameto

Customer profile

Segments4 records

Ideal customer profiles4 records

Gameto technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Gameto partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered flagship, core and minor.

  • Harvard University (Wyss Institute & Professor George Church's lab at Harvard Medical School)flagshipTechnology or Integration · 4 February 2026Gameto has exclusively licensed intellectual property from Harvard University related to the genetic induction of early meiosis in human cells. The licensed patent portfolio covers genes and methods enabling human oogonia to enter early meiotic stages in vitro and is integrated with Gameto's ovarian organoid platform. The collaboration underpins the company's scientific foundation (CSO Christian Kramme completed his PhD at Harvard Medical School under a Sponsored Research Agreement with Gameto and Professor George Church).
  • Prelude Fertility (Martin Varsavsky's network)flagshipStrategic or Co-development PartnerChairman Martin Varsavsky is the founder and non-executive chairman of Prelude Fertility, the largest network of fertility clinics in the United States. The Prelude network provides a potential channel and strategic alignment for Gameto's products and was identified as the founder's flagship prior company in the fertility space.
  • Boston IVF (Dr. Pietro Bortoletto)coreStrategic or Co-development PartnerDr. Pietro Bortoletto serves as a Scientific & Clinical Advisor to Gameto; he is Director of Reproductive Surgery and Co-Director of Oncofertility Program at Boston IVF and Clinical Instructor at Harvard Medical School. Boston IVF is a leading US fertility clinic network.
  • CCRM Fertility of New York (Dr. Jaime Knopman)coreStrategic or Co-development PartnerDr. Jaime Knopman, Director of Fertility Preservation at CCRM Fertility of New York, serves as a Scientific & Clinical Advisor to Gameto.
  • Ruber de Juan Bravo Hospital (Eugin Group; Dr. Daniel Ordóñez Pérez)coreImplementation/ SI/ Consulting PartnerDr. Daniel Ordóñez Pérez, Head of the Assisted Reproduction Unit at Ruber de Juan Bravo Hospital (part of Eugin Group), is a Scientific & Clinical Advisor and has conducted studies of Fertilo with his patients in Madrid, Spain.
  • Universitair Ziekenhuis Brussel (Dr. Michel De Vos)coreStrategic or Co-development PartnerDr. Michel De Vos, Senior Medical Director at the Centre for Reproductive Medicine at Universitair Ziekenhuis Brussel, Belgium, is a Scientific & Clinical Advisor to Gameto. He is a principal investigator in the FOTO consortium and a leading IVM expert.
  • Newcastle University / Newcastle Fertility Centre (Professor Mary Herbert)coreStrategic or Co-development PartnerProfessor Mary Herbert, Professor of Reproductive Biology at Newcastle University and Scientific Director at Newcastle Fertility Centre, serves as a Scientific & Clinical Advisor to Gameto.
  • Johns Hopkins University (Professor Philip Jordan; Dr. Joshua C. Doloff)minorStrategic or Co-development PartnerProfessor Philip Jordan (Biochemistry & Molecular Biology) and Dr. Joshua C. Doloff (Biomedical Engineering) at Johns Hopkins serve as Scientific & Clinical Advisors to Gameto.
  • Columbia University (Professor Kristin Baldwin)coreStrategic or Co-development PartnerProfessor Kristin Baldwin, Professor of Genetics and Development at Columbia University and member of the Columbia Stem Cell Initiative, serves as a Scientific & Clinical Advisor to Gameto.
  • Duke University Medical School (Professor Pranam Chatterjee)coreStrategic or Co-development PartnerProfessor Pranam Chatterjee, upcoming Assistant Professor at Duke University Medical School and Research Fellow at Harvard Medical School, serves as a Scientific & Clinical Advisor and is developing state-of-the-art algorithms and high-throughput experimental screens to interrogate germ cell development for Gameto. He holds patents on ScCas9, Sc++, and iSpyMac.
  • Accel Recruitment (clinical trial recruitment partner)coreImplementation/ SI/ Consulting PartnerAccel Recruitment hosts Gameto's Phase 3 US clinical trial eligibility screening and enrollment (accelrecruitment.com/ivf-study).

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Gameto competitors and assessment

Company assessment

Direct peers

  • Overture Life: Co-founded by Gameto Chairman Martin Varsavsky; focuses on automated IVF and embryo engineering. Direct comparable in cell-engineering-based reproductive medicine and shares scientific and investor DNA with Gameto.
  • Conceivable Life Sciences: Directly competes with Gameto in engineered egg maturation; co-recognized alongside Gameto at the 2025 World Fertility Awards in the same category. Closest head-to-head peer in iPSC/automation-driven IVF.

Emerging players

  • TMRW Life Sciences: Automated, software-tracked cryo-storage for frozen eggs and embryos; serves the same IVF/egg-freezing patient population as Fertilo with an adjacent technology layer rather than a cell-therapy approach.

Broad incumbents

  • Ferring Pharmaceuticals: One of the largest incumbents in reproductive medicine (Menopur, Bravelle, Lutrepulse) and a major commercial force in IVF drugs globally. Gameto's commercial advisor Aaron Graff is ex-CEO of Ferring USA, underscoring the direct competitive overlap.
  • Merck KGaA (Life Science / Healthcare): Sells Gonal-f (recombinant FSH), one of the gold-standard ovarian stimulation drugs for IVF. Sets the existing standard-of-care protocol that Fertilo's minimal-stimulation approach is designed to disrupt.
  • Organon & Co. Spun out of Merck with a focused women's health portfolio including fertility (e.g., Ganirelix, Follistim) and biosimilars. A likely strategic acquirer or competitor for any approved iPSC fertility therapy.
  • Vitrolife: Supplies IVF media, culture tools, and time-lapse incubation systems used in conventional IVF labs worldwide. Competes for clinic wallet share and partnership attention even though its offering is consumables rather than cell therapy.
  • Progyny: Public fertility benefits manager that sits between employers, clinics, and patients; relevant peer for understanding payer-side adoption dynamics and channel access that any approved Fertilo launch must navigate.
  • Kindbody: Operates a national network of fertility clinics and is also a major employer fertility benefits provider; competes with Gameto for clinic channel mindshare and represents a potential commercial partner or acquirer.

Others

  • BlueRock Therapeutics: Bayer-owned iPSC-derived cell therapy company (e.g., Parkinson's program); not a reproductive peer but a directly comparable iPSC platform company whose clinical and manufacturing trajectory informs investor expectations for Gameto's platform risk and timeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Gameto social profiles

Digital presence

Gameto financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gameto leadership team

Management profile

Number of profiles

Profiles12 records

Gameto funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gameto M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gameto

What does Gameto do?

Gameto is a clinical-stage biotechnology company that develops cell-engineered therapeutics for the female reproductive system using induced pluripotent stem cell (iPSC) technology. Its lead program, Fertilo, is an investigational OSC-IVM (ovarian support cell in vitro maturation) biologic that co-cultures immature oocytes with iPSC-derived ovarian support cells to mature eggs outside the body in approximately 24 hours, reducing the standard two-week IVF hormone injection protocol to about three days. The company also operates two additional programs: Ameno, a cell therapy targeting menopause symptoms, and Deovo, a drug screening platform for ovarian disease built on Gameto's licensed Harvard meiosis IP.

Is Gameto a public or private company?

Gameto is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gameto founded?

Gameto was founded in 2021. It employs 51 to 100 people.

Where is Gameto based?

Gameto is headquartered in New York, United States, in the North America region.

How does Gameto make money?

Three revenue lines are on record. Pre-commercial / Investigational therapy revenues are the primary driver. The others are non-dilutive grant funding (ARPA-H) and equity capital raises (private).

Who are Gameto's main competitors?

Direct peers on record are Overture Life and Conceivable Life Sciences. TMRW Life Sciences is listed as an emerging player. Broad incumbents are Ferring Pharmaceuticals, Merck KGaA (Life Science / Healthcare), Organon & Co., Vitrolife, Progyny and Kindbody. BlueRock Therapeutics is listed as an others.

Does Gameto have an API?

No public API is recorded for Gameto.

What industry is Gameto in?

Gameto's product category is Cell Therapy. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AlleyWatch#NYCtech Week in Review: 10/25/26 – 10/31/26NYC tech news for the week ending 10/31/26 covers multiple funding rounds and acquisitions, including Gameto's $1.38B acquisition by Ferring Pharmaceuticals, Kalshi's $1B Series G, and Hyphenate's $45M Series A. Other companies like Overwatch Data, ShareWillow, and Predicate also raised funds.El CronistaVarsavksy lo hizo de nuevo: una beca en Harvard, un duelo familiar y la venta de su sexto unicornioMartín Varsavsky sold Gameto, a fertility startup, for up to $1,380 million, his sixth unicorn. The company, founded from a Harvard scholarship, reduced IVF treatment time by 80%. He also supports President Milei's economic reforms and launched Certuma, an AI health startup.LA NACIONUn argentino fundador de cinco unicornios vendió su empresa de biotecnología por más de US$1380 millonesFerring Pharmaceuticals acquired Gameto, a biotech founded by Martín Varsavsky, for $1,382.5 million. Gameto's Fertilo product, which reduces fertility treatment injections, is in Phase 3 trials with 180 patients needed. Varsavsky said the team may continue collaborating on new products.Inc.This $1.4 Billion Deal Aims to Make Fertility Treatments Safer and More AffordableFerring Pharmaceuticals acquired Austin-based Gameto for $1.4 billion. Gameto's Fertilo technology matures eggs outside the body, reducing injections from about 12 days to three and lowering risk. The technology is in phase 3 trials, with executives expecting regulatory approval.Pharmaceutical TechnologyFerring bets on Gameto’s reproductive health solution through $1.38bn takeover - Pharmaceutical TechnologyFerring Pharmaceuticals agreed to acquire Gameto for up to $1.38bn, focusing on its Fertilo in vitro maturation program. Fertilo claims to shorten IVF and egg freezing from 14 to three days, with Phase III trials ongoing. The deal also adds Gameto's women's health pipeline, including Ameno and Deovo.The Pharma LetterFerring agrees to buy Gameto in deal worth up to $1.38 billionFerring Pharmaceuticals agreed to acquire US biotech Gameto for up to $1.38 billion, announced October 27. The deal includes milestone payments tied to development, regulatory, and commercial milestones, with no upfront payment or closing date disclosed. Both companies will operate independently until completion.BioPharma DiveFerring to acquire next-gen IVF startup Gameto for up to $1.4BFerring Pharmaceuticals agreed to acquire Gameto in a deal worth up to $1.4 billion, with payments tied to milestones. The acquisition adds Fertilo, a stem-cell-derived ovarian support technology that could compress IVF cycles to three days. Phase 3 testing is underway in the U.S.YahooFerring to acquire next-gen IVF startup Gameto for up to $1.4BFerring Pharmaceuticals agreed to acquire fertility startup Gameto in a deal worth up to $1.4 billion, with payments tied to milestones. The acquisition adds Fertilo, a stem-cell-derived ovarian support cell technology that could compress IVF cycles to three days. Phase 3 testing is underway in the U.S.LA NACIONMartín Varsavsky cerró un acuerdo millonario para vender su empresa de biotecnología y medicina reproductivaFerring Pharmaceuticals agreed to buy Gameto, a biotech firm founded by Martín Varsavsky, for $1.38 billion. Gameto's Fertilo product, which reduces ovulation injections, is in Phase 3 trials with 180 patients needed. Varsavsky said the team may continue collaborating on new products.AlleyWatchFerring Pharmaceuticals to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38BFerring Pharmaceuticals agreed to acquire Gameto, a fertility biotech, in a deal valued at up to $1.3825B, with price tied to milestones. Gameto's Fertilo program is investigational in the U.S., and a Phase 3 trial is underway with results expected in late 2026.